Nama's AI scorecard currently rates Ingevity Buy (6.3 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is NGVT's P/E ratio?

Ingevity trades at a trailing price-to-earnings ratio of 11.7.

When does NGVT report earnings?

Ingevity's next scheduled report is on Feb 24, 2027. Analysts expect EPS of $0.96.

What is the NGVT price target?

The median analyst price target from 3 analysts is $90.00, with a range of $85.00 – $92.00.

Is NGVT Shariah compliant?

Nama's AAOIFI-style screen reads Ingevity as Not Shariah Compliant. At least one of the three ratios or the industry test failed.

Nama Insights

Ingevity (NGVT)

Basic Materials · Specialty Chemicals · NYSE

Ingevity (NGVT) is a Basic Materials company in the Specialty Chemicals industry. It has a market capitalization of $2.07B, a trailing price-to-earnings ratio of 11.7 and a free-cash-flow yield of 12.6%. Over the most recent reported fiscal year, revenue declined 2.7% and free cash flow per share grew 437.8%. Nama's AI scorecard rates it Buy, 6.3 out of 10. On 12-month momentum it ranks in the leading band of its market.

AI scorecard

Buy · 6.3/10

Positive, at the low end of Buy. As of Nov 7, 2026.

Momentum

Leading · +53.5% over 12 months ex. last

Top 20% of its market on the past year's steady rise.

Shariah screen

Not Shariah Compliant

At least one of the three ratios or the industry test failed.

Off its high

-33.8%

How far the last close sits under the highest price of the past five years.

Market cap	$2.07B
Trailing P/E	11.7
Price / book	44.2
Price / sales	1.8
FCF yield	12.6%
Dividend yield	—
Gross margin	41.1%
Operating margin	24.5%
Net margin	4.7%
Revenue growth (YoY)	-2.7%
Revenue growth (3-yr annual)	-11.2%
EPS growth (YoY)	+26.5%
FCF/share growth (YoY)	+437.8%
Beta	1.1
Exchange	NYSE
Sector	Basic Materials
Industry	Specialty Chemicals

NGVT earnings

Next report: Feb 24, 2027 (Q4 2026, EPS estimate $0.96). Beat the EPS estimate in 3 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Nov 4, 2026	$1.63	$1.59	+2.5%	—
Q2 2026	Jul 29, 2026	$1.74	$1.33	+30.8%	$314.10M
Q1 2026	May 6, 2026	$1.15	$0.83	+38.5%	$258.00M
Q4 2025	Feb 25, 2026	$0.63	$0.65	-3.1%	$255.10M

NGVT analyst price target

Median target $90.00 from 3 analysts, ranging $85.00 – $92.00.

Specialty Chemicals peers

Ticker	Company	Market cap	P/E
LIN	Linde	$236.54B	30.9
ECL	Ecolab	$84.33B	37.4
SHW	Sherwin-Williams	$83.13B	28.9
APD	Air Products and Chemicals	$67.88B	22.7
PPG	PPG Industries	$27.03B	15.7
IFF	International Flavors & Fragrances	$20.69B	22.3
LYB	LyondellBasell Industries	$19.63B	8.6
DD	DuPont de Nemours	$19.42B	20.9

Explore live NGVT data on Nama Insights →

NGVT FAQ

Is NGVT a buy?: Nama's AI scorecard currently rates Ingevity Buy (6.3 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is NGVT's P/E ratio?: Ingevity trades at a trailing price-to-earnings ratio of 11.7.
When does NGVT report earnings?: Ingevity's next scheduled report is on Feb 24, 2027. Analysts expect EPS of $0.96.
What is the NGVT price target?: The median analyst price target from 3 analysts is $90.00, with a range of $85.00 – $92.00.
Is NGVT Shariah compliant?: Nama's AAOIFI-style screen reads Ingevity as Not Shariah Compliant. At least one of the three ratios or the industry test failed.